Study to Evaluate the Safety of SP-104

Phase 1, Double-blind, Randomized, 2-Period, 2-Treatment Crossover Study to Evaluate the Safety of SP-104 Compared to Immediate Release Naltrexone Capsules in Healthy Adult Subjects

Evaluate the safety and tolerability of 3-day repeat-dose of SP-104 compared to naltrexone hydrochloride immediate release.

Study Overview

• Status: Completed
• Conditions: Healthy Volunteers
• Intervention / Treatment: Drug: SP-104; Drug: Naltrexone immediate release oral capsules

Detailed Description

The purpose of this trial is to evaluate the safety and tolerability of SP-104 relative to naltrexone immediate release capsules in healthy adults. The study is designed to test the hypothesis that the formulation of SP-104 will mitigate against adverse events associated with naltrexone.

• Study Type: Interventional
• Enrollment (Actual): 52
• Phase: Phase 1

Contacts and Locations

Study Locations

• New Zealand
  • Auckland, New Zealand, 1010
    • Auckland Clinical Studies (NZCR)
  • Christchurch, New Zealand, 8011
    • Christchurch Clinical Studies Trust (NZCR)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Able and willing to read, write, and understand the English language and provide English language written informed consent (IC) prior to beginning any study procedures.
2. Male or female age 18 to 70 years (inclusive) at screening.
3. Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs, or electrocardiogram (ECG), as deemed by the Investigator.
4. Negative urine drug screen for drugs of abuse, including cocaine, marijuana, amphetamines, and barbiturates at the Screening Visit and at each check-in.
5. If female, heterosexually active, of childbearing potential, not pregnant, not trying to become pregnant, or lactating, individuals are eligible to participate if participants agree to total abstinence from heterosexual intercourse, from screening through until at least 30 days after the last study dose, or to the use of an effective method listed below, from screening through until at least 30 days after the last study dose. A second non-hormonal method of contraception is required if a hormonal form of birth control is used. Females of childbearing potential must have negative pregnancy tests at Screening and on admission.
6. If male and heterosexually active, individuals are eligible to participate if participants agree to total abstinence from heterosexual intercourse, from screening through until at least 90 days after the last study dose, or to the use of an effective method listed below, from screening through until at least 90 days after the last study dose.
7. Able to swallow capsules.
8. Agrees to comply with all study requirements throughout the entire study period.

Exclusion Criteria:

1. A body mass index (BMI) <18 kg/m2 or >30 kg/m2 (without rounding).
2. Are using prescription medications or over-the-counter products (including dietary supplements such as vitamins, minerals, herbs or other botanicals, amino acids, enzymes (extracts or concentrates), or probiotics (bacteria or yeasts), within 14 days prior to administration of the study medication.
3. Currently using or have recently used opioids
4. Use of any other investigational drug within 30 days prior to administration of the study medication.
5. History of allergic or adverse response to naltrexone.
6. History of drug or alcohol abuse (>80 g/day).
7. History of sleep apnea or restless leg syndrome.
8. Serology positive for hepatitis B surface antigen, hepatitis C antibodies, or human immunodeficiency virus (HIV) antibodies.
9. Positive for known disease (e.g., corona virus disease 2019 (COVID-19 )).
10. Subjects with current or past SARS-CoV-2 infection, if tested according to local requirements.
11. Have had a serious illness in the 4 weeks preceding the Screening Visit that resulted in missed work or hospitalization (note: missed work in itself may not denote serious illness).
12. Have cancer within the past 5 years (treated or untreated).
13. Are females who are pregnant, plan to become pregnant during the study, or are breastfeeding.
14. Are an employee, family member, sponsor, or student of the Investigator or of the clinical site.
15. Are unable to understand or adhere to the requirements of the protocol.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: SP-104 crossover to naltrexone immediate release; SP-104 administration followed by a crossover to naltrexone immediate release oral capsule administration	Drug: SP-104; oral capsule once daily; Drug: Naltrexone immediate release oral capsules; oral capsule once daily
Experimental: Naltrexone immediate release crossover to SP-104; Naltrexone immediate release oral capsule administration with a crossover to SP-104 administration	Drug: SP-104; oral capsule once daily; Drug: Naltrexone immediate release oral capsules; oral capsule once daily

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Incidence of treatment emergent adverse events	1 week

Collaborators and Investigators

• Sponsor: Scilex Pharmaceuticals, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): October 4, 2021
• Primary Completion (Actual): December 20, 2021
• Study Completion (Actual): December 20, 2021

Study Registration Dates

• First Submitted: July 6, 2021
• First Submitted That Met QC Criteria: July 6, 2021
• First Posted (Actual): July 12, 2021

Study Record Updates

• Last Update Posted (Actual): January 31, 2022
• Last Update Submitted That Met QC Criteria: January 28, 2022
• Last Verified: January 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Peripheral Nervous System Agents; Sensory System Agents; Narcotic Antagonists; Alcohol Deterrents; Naltrexone
• Other Study ID Numbers: SP-104-02

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No